screener
SolarEdge -13.3%: in week 21, the sell signal's short stands 53.91% in profit
SolarEdge stock falls 13.3% as the sell signal, in week 21, lifts the short to a 53.91% gain. The trade is in its management phase: our model suggests staying disciplined on a position that has already built a large gain.
SCHX +2.6%: sell signal in week 3, opening a short carries high risk
SCHX, the Schwab U.S. large-cap ETF, rises 2.6% with its sell signal now in week 3. Our model rates opening a short at this stage as high risk, and it keeps tracking the ETF week by week to see how the case develops.
Charles Schwab +1.6%: sell signal in week 9, with the short up 11.66%
Charles Schwab stock gains 1.6%, while the sell signal, now in week 9, is in its management phase. The short is 11.66% in profit, and our model suggests protecting the gain with disciplined management of the position.
SCHF +2.1%: sell signal in week 7, with the short still in profit
SCHF, the international equity ETF, rises 2.1% on the week, with its sell signal now in week 7. Our model sees the trade in its management phase, with the short still 2.28% in profit and no new action on the table.
SCHE +1.7%: the emerging markets sell signal moves into its management phase
SCHE, the emerging markets ETF, rises 1.7% as its sell signal, now in week 5, moves into the management phase. In this technical analysis, the short still shows a 2.94% gain and our model points to managing the open position with discipline.
SCHB ETF +2.5%: sell signal in week 9, with the short still in profit
SCHB, the broad US equity market ETF, gains 2.5% on the week while its sell signal is in week 9. In our technical analysis of this ETF, the model keeps the short, now up 1.33%, in its management phase.
Starbucks +1.0%: the buy signal in week 3 stands 5.6% up since entry
Starbucks stock gains 1.0% and the buy signal, now in week 3, is 5.60% up since entry. Our model indicates a standard position size and sets the next scaling-out window in week 6, for 10% of the position.
Sabesp +1.6%: the early-exit warning on the short remains in force
Trading latinoamerica: Sabesp stock gains 1.6% as the sell signal sits in week 3, with the short down 10.20%. Our model keeps its early-exit warning in force and advises against opening a fresh short.
Sanofi +4.6%: the buy signal stretches to a 9.86% gain in week 2
Sanofi stock gains 4.6%, and the buy signal, now in week 2, stands 9.86% up since entry. Our model indicates a standard position size, with the next scaling-out window due in week 6, for 10% of the position.
Safran +3.8%: a new buy signal kicks in with a standard position size
Safran stock gains 3.8% on the week and triggers a new buy signal on Euronext. Our model indicates a standard position size, with the first scaling-out window set for week 6, covering 10% of the position.
Recursion Pharmaceuticals -9.5%: short up 13.92%, first target passed
Recursion Pharmaceuticals stock falls 9.5%, with the sell signal in week 4 and the short up 13.92%. The first target has already been passed, while our model advises against opening a fresh short at this stage.
RTX +4.8%: the early-exit warning still stands in week 2 of the buy signal
RTX stock gains 4.8% with the buy signal in week 2, still 0.61% below entry. For our model the early-exit warning remains in place, and our statistics suggest closing the trade here, at this early stage.
Hermes International -1.5%: the short is 33.88% in profit in week 42
Hermes International stock slips 1.5% while the sell signal, now in week 42, stays in its management phase. The short is 33.88% in profit, and our model suggests handling it with discipline, with no rush to close.
Rocket Lab +15.9%: the short stays in its management phase, 44.10% in profit
Rocket Lab stock jumps 15.9% on the week, while the sell signal, now in week 24, stays in its management phase. The short still holds a 44.10% gain, and our model suggests keeping the existing position under disciplined management.